Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.64 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.64 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.64 |
| ▸ | MAOB | P27338 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | APEX1 | P27695 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13142806 | 0.83 | KMT2A (0.62) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 | |
| SCHEMBL23249749 | 0.82 | KMT2A (0.66) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL30698159 | 0.81 | KMT2A (0.69) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL363937 | 0.81 | — | — | |
| SCHEMBL2834430 | 0.81 | RAB9A (1.00) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL10829218 | 0.81 | KMT2A (0.61) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL10682751 | 0.80 | ALDH1A1 (0.66) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| Hydrochloric Acid SCHEMBL11748963 | 0.80 | KMT2A (0.67) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL15056924 | 0.79 | KMT2A (0.61) | KMT2ASMN1; SMN2NPC1RAB9ATP53 | |
| SCHEMBL459833 | 0.78 | MEN1 (0.68) | KMT2ASMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2025-12-30 | — | — | US | disclosed |
| EP-3515904-B1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2024-01-17 | — | — | EP | disclosed |
| CN-110234640-B | Benzimidazole derivatives as anticancer agents | 利昂贝拉尔中心 | 2023-04-07 | — | — | CN | disclosed |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | CENTRE LEON BERARD (FR) | 2022-11-03 | — | — | US | disclosed |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | CENTRE LEON BERARD (FR) | 2022-07-12 | — | — | US | disclosed |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2021-09-23 | — | — | US | disclosed |
| EP-3515904-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | Centre Leon Berard (FR) | 2019-07-31 | — | — | EP | disclosed |
| WO-2018054989-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | CENTRE LEON BERARD (FR) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12509465-B2 | Benzoimidazole derivatives as anticancer agents | CCAR2, MAPKAP1, BCOR | KMT2A 3941/4885SMN1; SMN2 2392/4885NPC1 1805/4885 |
| US-20210292328-A1 | BENZOIMIDAZOLE DERIVATIVES AS ANTICANCER AGENTS | TMBIM6, BAX, MAPK14 | KMT2A 3022/4885SMN1; SMN2 3155/4885NPC1 3255/4885 |
| US-11384081-B2 | Benzoimidazole derivatives as anticancer agents | TMBIM6, BAX, MAPK14 | KMT2A 3022/4885SMN1; SMN2 3155/4885NPC1 3255/4885 |
| US-20220348587-A1 | Benzoimidazole Derivatives As Anticancer Agents | TMBIM6, BAX, BCL2 | KMT2A 3028/4885SMN1; SMN2 3174/4885NPC1 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.